3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
5
Phase NA
2
Phase 4
2
Phase 2
2
Status
Recruiting
1
Completed
1
Sponsor Class
OTHER
2
Study Type
Interventional
2
Sponsor
Cancer Type
Classical hematology
1
Conditions
Venous Thromboembolism
3
Neoplasms
2
Venous Thrombosis
1
Upper Extremity Deep Vein Thrombosis
1
Thrombosis
1
Multiple Myeloma
1
Head and Neck Neoplasms
1
Fibrosis
1
Catheter-Related Infections
1
Carcinoma, Hepatocellular
1
Interventions
Dexamethasone
8
Oxycodone
6
Epoetin Alfa
5
Propofol
4
Palonosetron
4
Meropenem
4
Zoledronic Acid
3
Vancomycin
3
Sevoflurane
3
Ondansetron
3
Naloxone
3
Everolimus
3
Ciprofloxacin
3
Cholecalciferol
3
Ceftazidime
3
Cefepime
3
Calcium Dobesilate
3
Bevacizumab
3
Aspirin
3
Aprepitant
3
peginterferon alfa-2a
2
edoxaban
2
apixaban
2
apatinib
2
Vitamin B 12
2
Vincristine
2
Tobacco Use Cessation Devices
2
Teicoplanin
2
Tablets
2
Surgical Procedures, Operative
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Phase 4
×
Neoplasms
×
apixaban
×
Clear all
NCT06603870
2025-05-30
STREAM-Line
Ottawa Hospital Research Institute
Phase 4
Recruiting
330 enrolled
NCT02581176
2018-06-26
CAP
University Hospital, Akershus
Phase 4
Completed
300 enrolled